本页面由Tiger Trade Technology Pte. Ltd.提供服务

CRISPR Therapeutics AG

55.72
-1.0400-1.83%
盘后55.46-0.2600-0.47%19:24 EDT
成交量:171.34万
成交额:9,523.01万
市值:53.48亿
市盈率:-8.61
高:57.24
开:56.84
低:54.57
收:56.76
52周最高:78.48
52周最低:33.03
股本:9,598.53万
流通股本:9,053.30万
量比:1.08
换手率:1.89%
股息:- -
股息率:- -
每股收益(TTM):-6.4700
每股收益(LYR):-6.4700
净资产收益率:-30.18%
总资产收益率:-15.76%
市净率:2.78
市盈率(LYR):-8.61

数据加载中...

2019/06/26

重要事件披露

Current report, item 8.01
2019/06/19

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Initial statement of beneficial ownership of securities
2019/06/13

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/13

持股变动声明

Initial statement of beneficial ownership of securities
2019/06/13

重要事件披露

Current report, items 5.02, 5.03, 5.07, and 9.01
2019/06/12

持股变动声明

Statement of changes in beneficial ownership of securities
2019/06/07

超过5%披露

[Amend] General statement of acquisition of beneficial ownership
2019/06/06

重要事件披露

Current report, items 1.01, 8.01, and 9.01
2019/06/04

持股变动声明

Statement of changes in beneficial ownership of securities
2019/04/29

SEC问询函

[Cover]Correspondence
2019/04/23

SEC问询函

[Cover]Correspondence
2018/12/28

超过5%披露

[Amend] General statement of acquisition of beneficial ownership
2018/12/26

超过5%披露

[Amend] General statement of acquisition of beneficial ownership
2018/02/13

超过5%披露